搜尋
Bristol-Myers Squibb Co
BMY添加自選
55.690USD
+0.160+0.29%
收盤 06/23, 16:00（美東）報價延遲15分鐘
113.72B總市值
15.59本益比TTM
關鍵數據
55.060今開
55.935最高
1.57K成交量
15.59本益比TTM
9.04本益比動
2.500股利TTM
0.00%換手率
55.530昨收
54.960最低
15.46K成交額
虧損本益比靜
5.67市淨率
4.49%股息率 TTM
8.13%ROA
62.88652週最高
-0.00量比
-8.95B淨利潤
2.04B總股本
3.5723每股盈餘TTM
0.24Beta
38.84%ROE
42.52052週最低
1.76%振幅
66.53%毛利率
113.72B總市值
-4.85回報/風險
1.36%風險率
TradingKey Bristol-Myers Squibb Co股票評分
單位: USD 更新時間: 2026-06-23操作建議
Bristol-Myers Squibb Co當前公司基本面數據相對健康，增長潛力很大。當前估值合理，在藥品行業排名57/157位。機構持股佔比非常高，近一月多位分析師給出公司評級為持有。最高目標價為62.06。中期看，股價處於平穩狀態。近一個月，市場表現一般，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Bristol-Myers Squibb Co評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
46°C
過冷
過熱
中性
Bristol-Myers Squibb Co亮點
亮點風險
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
業績轉盈
公司業績轉盈，最新年度盈利美元
估值合理
公司最新PE估值15.54，處於3年歷史合理位
機構減倉
最新機構持股1.72B股，環比減少0.65%
理查德·皮茲納持倉
明星投資者理查德·皮茲納持倉，最新持倉17.91M股
分析師目標
基於
32
分析師
持有
評級
62.057
目標均價
+13.45%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Bristol-Myers Squibb Co新聞
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Bristol-Myers Squibb Co簡介
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
公司代碼BMY
公司Bristol-Myers Squibb Co
CEOBoerner (Christopher S)
網址https://www.bms.com
相關品種
+0.54%
-0.35%
+0.27%
0.00%
0.00%
-0.55%
0.00%
-1.71%
0.00%
+0.18%
0.00%
0.00%
+0.29%
0.00%
0.00%
0.00%
+3.14%
0.00%
+0.06%熱門品種
71.009
-1.936 (-2.65%)
296.050
+1.750 (+0.59%)
201.314
+1.274 (+0.64%)
4019.100
-91.650 (-2.23%)
680.465
+9.715 (+1.45%)
2020.000
+56.400 (+2.87%)
1092.599
+40.829 (+3.88%)
347.479
+1.349 (+0.39%)
62816.000
+375.300 (+0.60%)
383.700
+2.090 (+0.55%)
常見問題
Bristol-Myers Squibb Co(BMY)的當前股價是多少？
Bristol-Myers Squibb Co(BMY)的當前股價是 55.53。
Bristol-Myers Squibb Co 的股票代碼是什麼？
Bristol-Myers Squibb Co的股票代碼是BMY。
Bristol-Myers Squibb Co股票的52週最高點是多少？
Bristol-Myers Squibb Co股票的52週最高點是62.89。
Bristol-Myers Squibb Co股票的52週最低點是多少？
Bristol-Myers Squibb Co股票的52週最低點是42.52。
Bristol-Myers Squibb Co的市值是多少？
Bristol-Myers Squibb Co的市值是113.40B。
現在Bristol-Myers Squibb Co(BMY)的股票是買入、持有還是賣出？
根據分析師評級，Bristol-Myers Squibb Co(BMY)的總體評級為signal_hold，目標價格為62.06。
Bristol-Myers Squibb Co(BMY)股票的每股收益（EPS TTM）是多少
Bristol-Myers Squibb Co(BMY)股票的每股收益（EPS TTM）是3.47。
